Background: The proper management of postoperative pain improves patients' quality of life, accelerates early postoperative recovery, shortens hospitalization period, and reduces medical costs. This study aimed to compare the effectiveness of intravenous fentanyl pump and sublingual buprenorphine tablet in controlling pain after open cholecystectomy.
Objectives: Evaluating the effectiveness of sublingual buprenorphine in reducing postoperative pain and complications after open cholecystectomy.
Methods: This study was a double-blind, randomized clinical trial. The study population encompassed those candidates undergoing open cholecystectomy, patients with ASA class I and II, individuals undergoing no other concomitant surgery, and patients in the age range of 20 - 50 years. The first group received sublingual buprenorphine 6, 12, and 18 hours after the first administration. The second group received fentanyl as patient-controlled analgesia (PCA) for 24 hours. Then nausea, vomiting, sedation, and Visual Analog Scale (VAS) scores were evaluated at the beginning, 2, 6, 12, 18, and 24 hours after surgery. The collected data were analyzed using SPSS software version 20.
Results: The mean age of the patients in the buprenorphine and fentanyl groups were 44.8 ± 5.5 and 42.8 ± 7.1 years, respectively. In this study, 22.5% of the patients in the buprenorphine group and 35.5% of the patients in the fentanyl group were male. During 6 and 24 hours after surgery, the pain level regarding the VAS scores was significantly lower in the buprenorphine group than in the fentanyl group; however, analgesic consumption was higher in the fentanyl group. In the early hours after surgery (2 and 6 hours), nausea and vomiting were lower in the buprenorphine group than in the fentanyl group even though the difference was not significant.
Conclusions: This study suggests buprenorphine as an effective drug for patients to reduce postoperative pain because of its limited complications, inexpensiveness, and more convenient administration method.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438705 | PMC |
| http://dx.doi.org/10.5812/aapm.113909 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase 1b/2a safety study of lemborexant as an adjunctive treatment for insomnia to buprenorphine-naloxone for opioid use disorder: A randomized controlled trial.
Drug Alcohol Depend Rep
March 2025
Institute for Drug and Alcohol Studies, Virginia Commonwealth University, 203 East Cary Street, Richmond, VA 23219, USA.
Background: Evidence supports the common incidence of sleep disturbance in opioid use disorder (OUD) as a potential marker of disrupted orexin system functioning. This study evaluated the initial safety and tolerability of a challenge dose of lemborexant, a dual orexin antagonist, as an adjunct to buprenorphine/naloxone.
Methods: Patients (18-65 years old) with OUD receiving sublingual buprenorphine/naloxone, with a Pittsburgh Sleep Quality Index total score of 6 or higher, were recruited from outpatient clinics.
Efficacy and safety of sublingual buprenorphine in managing acute postoperative pain - A systematic review.
J Anaesthesiol Clin Pharmacol
July 2024
Department of Pediatric Surgery, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Sublingual (SL) buprenorphine has been used as a modality of managing acute postoperative pain in many studies. This systematic review aimed to investigate the safety and efficacy of SL buprenorphine as an analgesic for various surgeries. After registering the protocol with PROSPERO, we searched PubMed, Cochrane Library, and Ovid databases with relevant keywords.
View Article and Find Full Text PDFEvaluating the use of sublingual sufentanil in patients with buprenorphine treatment who are undergoing ambulatory surgery: A Prospective Case Report.
Orthop Rev (Pavia)
December 2024
Anesthesiology Montefiore Medical Center, Albert Einstein College of Medicine.
Introduction: Opioid use disorder is a chronic illness with significant morbidity and mortality. Opioid agonists, like buprenorphine, are commonly used to prevent relapse. Recent changes in buprenorphine legislation are expected to increase prescription and guidelines recommend its continuation during the perioperative period for many patients.
View Article and Find Full Text PDFThe Effect of Out-of-Pocket Costs on Medications for Opioid Use Disorder and Overdose: A Scoping Review.
J Am Pharm Assoc (2003)
December 2024
College of Pharmacy, Faculty of Health, Dalhousie University, Halifax, NS, Canada. Electronic address:
Background: The opioid epidemic is a major public health crisis in Canada and elsewhere. The increase in opioid prescriptions is a major contributor to this crisis. Medications for opioid use disorder (OUD) and overdose are effective and life saving treatments.
View Article and Find Full Text PDFExploring Opioid Use Disorder Outcomes by Quantitative Urinalysis: Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.
J Addict Med
December 2024
From Camurus AB, Lund, Sweden (SP, FT); New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY (EVN); and Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington, KY (MRL, SLW).
Article Synopsis
- Opioid use disorder (OUD) is a pressing global issue, and while urine drug screenings help monitor treatment responses, they typically provide only yes/no results, complicating comparisons between studies due to varying analytical cutoffs.
- This study analyzed data from a 31-week trial involving 428 participants to compare the efficacy of CAM2038 (subcutaneous buprenorphine) to daily sublingual buprenorphine/naloxone, using quantitative urine drug tests to evaluate different cutoffs for opioid detection.
- Results showed that higher cutoff values led to more pronounced differences in treatment effectiveness favoring CAM2038, suggesting that quantitative urinalysis can offer
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!